購読する
モデル製品
カスタムサービス
創薬研究
コミュ二ティー
huTROP2(TACSTD2)(2) Mouse
製品のお見積りを依頼する
当社のカタログから製品を選択してご注文ください。当社チームが詳細な情報をご連絡いたします。
huTROP2(TACSTD2)(2) Mouse
製品名
huTROP2(TACSTD2)(2) Mouse
製品ID
C002143
系統名
C57BL/6Cya-Tacstd2tm2(hTACSTD2)/Cya
背景情報
C57BL/6Cya
状況
このマウス系統を論文で使用する場合は、「huTROP2(TACSTD2)(2) Mouse(カタログ番号C002143)はサイアジェンから購入しました。」と引用してください。
HUGO-GT Humanized ModelsTumor Target Humanized Mouse Models
mAb
BsAb
MsAb
TCE
ADC
siRNA
In Vivo CAR-T
CAR-T
CAR-NK
製品タイプ
年齢
遺伝子型
性別
数量
標準的な配送方法では、少なくとも3匹のヘテロ接合体キャリアを保証しています。ホモ接合体キャリアや指定された性別の個体の繁殖サービスも利用可能です。
お見積もりについてはこちらまでご連絡ください
HUGO-GT Humanized ModelsTumor Target Humanized Mouse Models
mAb
BsAb
MsAb
TCE
ADC
siRNA
In Vivo CAR-T
CAR-T
CAR-NK
基本情報
関連リソース
基本情報
遺伝子名
遺伝子別名
EGP1, GP50, M1S1, EGP-1, TROP2, GA7331, GA733-1
NCBI ID
染色体
Chr 1
MGI ID
さらに
系統詳細
Tumor-associated calcium signal transducer 2 (TROP2), encoded by the TACSTD2 gene, is an important type I transmembrane glycoprotein that plays a critical regulatory role in multiple cellular biological processes. As a typical cell surface receptor, TROP2 induces intracellular calcium release by transducing extracellular signals, thereby regulating key biological behaviors such as cell proliferation, adhesion, migration, and differentiation [1]. Under normal physiological conditions, TROP2 is highly expressed during embryonic development (particularly in fetal tissues and trophoblast cells), while only basal expression levels are maintained in some adult normal epithelial tissues. However, TROP2 expression is significantly and aberrantly upregulated in a variety of human malignant tumors, a feature that makes it an important tumor marker [2]. Studies have shown that dysregulated TROP2 expression can promote tumor initiation, progression, and metastasis through the activation of multiple signaling pathways [3]. In addition to its oncogenic role, germline mutations in the TACSTD2 gene have also been confirmed as the causative factor for gelatinous drop-like corneal dystrophy, a rare autosomal recessive disorder [4]. Notably, TROP2 expression is restricted in most normal adult tissues but is highly enriched in various solid tumors. This highly selective expression pattern makes it a highly promising therapeutic target [3].
The huTROP2(TACSTD2)(2) mouse is a humanized mouse model generated through a gene editing strategy, in which the exon 1 plus flanking region of mouse Tacstd2 gene was replaced with the exon 1 plus flanking region of human TACSTD2 gene. The humanized sequence contains the UTR region of the human TACSTD2 gene. This strain can be used for studying the pathogenesis of various solid tumors, as well as for the screening, development, and in vivo evaluation of TACSTD2-targeted drugs.
A comparable hTROP2(TACSTD2) mouse (signal peptide and extracellular domain-humanized model; Catalog No.: C001718) has also been developed by Cyagen. The two strains differ in the composition of the humanized expression elements: only the signal peptide and extracellular domain are humanized in C001718, whereas the human TACSTD2 exon 1 (including the UTR) together with its upstream and downstream flanking sequences is humanized in this model. The appropriate model should be selected according to the research purpose.
参考文献
Liu X, Ma L, Li J, Sun L, Yang Y, Liu T, Xing D, Yan S, Zhang M. Trop2-targeted therapies in solid tumors: advances and future directions. Theranostics. 2024 Jun 11;14(9):3674-3692.
Wen Y, Ouyang D, Zou Q, Chen Q, Luo N, He H, Anwar M, Yi W. A literature review of the promising future of TROP2: a potential drug therapy target. Ann Transl Med. 2022 Dec;10(24):1403.
Jiang Y, Zhou H, Liu J, Ha W, Xia X, Li J, Chao T, Xiong H. Progress and Innovative Combination Therapies in Trop-2-Targeted ADCs. Pharmaceuticals (Basel). 2024 May 17;17(5):652.
Tsujikawa M. Gelatinous drop-like corneal dystrophy. Cornea. 2012 Nov;31 Suppl 1:S37-40.
系統作製戦略
The exon 1 plus flanking region of mouse Tacstd2 gene was replaced with the exon 1 plus flanking region of human TACSTD2 gene.

Figure 1. Gene editing strategy of huTROP2(TACSTD2)(2) mice.
適用分野
Screening, development, and evaluation of TACSTD2-targeted drugs;
Research on the pathological mechanisms of various malignant tumors;
Research on the pathological mechanisms and therapeutic approaches for gelatinous drop-like corneal dystrophy.
関連リソース
お問い合わせ
カスタムの動物モデルに関するご相談は、下記のフォームにご記入いただき、ご連絡いただくか見積もりをご依頼ください。
Cyagenはお客様のプライバシーを大変重視しています。当社の最新の製品や情報をお届けしたいと思っています。お客様の設定をご確認ください。
これらの配信はいつでも解除できます。配信停止方法およびデータ保護の詳細は プライバシーポリシー をご確認ください。
以下のボタンをクリックすることで、このフォームにご入力いただいた個人情報をCyagenが保存・処理し、ご要望のコンテンツを提供することに同意されたことになります。
